CA2248782A1 - Peptides lytiques - Google Patents

Peptides lytiques Download PDF

Info

Publication number
CA2248782A1
CA2248782A1 CA002248782A CA2248782A CA2248782A1 CA 2248782 A1 CA2248782 A1 CA 2248782A1 CA 002248782 A CA002248782 A CA 002248782A CA 2248782 A CA2248782 A CA 2248782A CA 2248782 A1 CA2248782 A1 CA 2248782A1
Authority
CA
Canada
Prior art keywords
peptide
omega
terminal
amphipathic
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248782A
Other languages
English (en)
Inventor
Donald Edward Rivett (Deceased)
Peter John Hudson
Jerome Anthony Werkmeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2248782A1 publication Critical patent/CA2248782A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un peptide à activité lytique, ayant une hélice .alpha. amphiphatique d'une longueur suffisante et d'une nature appropriée, pour permettre au peptide d'avoir une activité lytique. L'extrémité N-terminale et/ou l'extrémité C-terminale de ce peptide comprend un ou plusieurs groupes qui produisent une augmentation de la charge positive du peptide par rapport à la charge du peptide ayant la même séquence d'aminoacides et la même structure, mais ne comprenant pas ce ou ces groupes. L'invention concerne, également, des procédés d'activation et d'inactivation de la fonction lytique, des compositions pharmaceutiques et des méthodes de traitement.
CA002248782A 1996-03-13 1997-03-13 Peptides lytiques Abandoned CA2248782A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN8614 1996-03-13
AUPN8614A AUPN861496A0 (en) 1996-03-13 1996-03-13 Lytic peptides

Publications (1)

Publication Number Publication Date
CA2248782A1 true CA2248782A1 (fr) 1997-09-18

Family

ID=3792926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248782A Abandoned CA2248782A1 (fr) 1996-03-13 1997-03-13 Peptides lytiques

Country Status (6)

Country Link
EP (1) EP0901502A4 (fr)
AU (1) AUPN861496A0 (fr)
CA (1) CA2248782A1 (fr)
NZ (1) NZ331771A (fr)
WO (1) WO1997033908A1 (fr)
ZA (1) ZA972186B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705519D0 (en) * 1997-03-18 1997-05-07 Anmat Technology Limited Activation of peptides
JP2003533165A (ja) * 1998-07-09 2003-11-11 ユニバーシティー・オブ・サウザーン・カリフォルニア ウイルスエンベロープタンパク質の細胞質末端由来の分離された両親媒性ペプチド
JP2002525382A (ja) 1998-09-25 2002-08-13 ザ チルドレンズ メディカル センター コーポレイション プロテインキナーゼの活性を選択的に調節するショートペプチド
JP2003502010A (ja) * 1998-11-18 2003-01-21 インナチュレ リミテッド 産 物
GB9926875D0 (en) 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
US7094750B2 (en) 2000-05-09 2006-08-22 Greenville Hospital System Therapeutic pore-forming peptides
WO2003089455A2 (fr) 2002-04-22 2003-10-30 Dow Global Technologies Inc. Production de peptides a bas prix
AU2008251748B2 (en) * 2007-01-16 2014-02-27 C3 Jian, Inc. Novel antimicrobial peptides
US8497353B2 (en) 2008-02-14 2013-07-30 3M Innovative Properties Company Polypeptides for microbial detection
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof

Also Published As

Publication number Publication date
EP0901502A4 (fr) 2001-09-26
EP0901502A1 (fr) 1999-03-17
ZA972186B (en) 1997-11-10
AUPN861496A0 (en) 1996-04-04
NZ331771A (en) 2000-04-28
WO1997033908A1 (fr) 1997-09-18

Similar Documents

Publication Publication Date Title
Mazel et al. Doxorubicin-peptide conjugates overcome multidrug resistance
CA2191862C (fr) Peptide ramifie de synthese utilise comme ligand
KR100447696B1 (ko) 펩타이드 맥관형성 억제 약제
US20070104719A1 (en) Caspase Activated Prodrugs Therapy
US8632972B2 (en) Methods and compositions for identifying RNA-binding proteins
ES2211899T3 (es) Producto para la inhibicion de la apoptosis, compuestos adecuados para ello y preparacion de los mismos.
KR20230090368A (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
UA55371C2 (uk) Олігопептид, який розпізнається та протеолітично розщеплюється вільним простатичним антигеном, спосіб визначення протеолітичної активності вказаного антигену, спосіб ідентифікації сполук, які інгібують протеолітичну активність вказаного антигену, кон'югат, який використовують для лікування раку передміхурової залози
JPH06508742A (ja) 組換えトロンビンレセプターおよびそれに関連した薬剤
EP0767674A1 (fr) Procede permettant d'inhiber la fixation de l'integrine alpha 4 beta 1 a la molecule d'adherence cellulaire vasculaire 1 ou a la fibronectine
CN101421298A (zh) 用于治疗免疫相关疾病的新组合物和方法
CA2170390A1 (fr) Sequence peptidique immunoreactive provenant de l'antigene tumoral humain 43 kd
CN102143970A (zh) α-促黑素细胞激素的肽类似物
CA2000821A1 (fr) Inhibiteurs de l'agglomeration des plaquettes
BG64768B1 (bg) Конюгати, приложими при лечение на рак на простата
CA2248782A1 (fr) Peptides lytiques
CA2174943A1 (fr) Nouvelle proteine inactivant les ribosomes isolee a partir de la plante bryonia dioica
US6469138B1 (en) Thrombospondin receptor binding peptides
WO2002094853A2 (fr) Anticorps specifiques du poly(ethylene glycol)
US5952471A (en) Antibody that binds to cluster w-4 polypeptide of human small cell lung carcinoma cells
KR20200032184A (ko) 환상 펩티드를 단백질 구조에 제시시키는 초범용법
RU2439077C2 (ru) Белоксвязывающие производные метотрексата и содержащие их лекарства
WO2015143581A1 (fr) Protéine de fusion à double mutant à spécificité de cible et son procédé de fabrication
KR20150083600A (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP7179855B2 (ja) 低ｐＨ挿入ペプチド及びその組成物

Legal Events

Date Code Title Description
FZDE Discontinued